Steris ( (STE) ) has released its Q4 earnings. Here is a breakdown of the information Steris presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
STERIS plc, a global leader in infection prevention and healthcare solutions, has reported its financial results for the fourth quarter and full fiscal year 2025, showcasing steady growth and a positive outlook for the future. The company operates in the healthcare and life sciences sectors, providing innovative products and services that enhance patient care and safety.
In its fiscal 2025, STERIS achieved a 6% increase in revenue from continuing operations, reaching $5.5 billion, with a constant currency organic revenue growth of 6%. The company also reported a rise in adjusted earnings per share to $9.22, reflecting robust performance across its diverse customer base and increased global procedure volumes. The fourth quarter alone saw a 4% revenue increase, driven by strong service and consumable revenue growth.
Key financial highlights include a net income from continuing operations of $610.1 million for the full year, with a diluted EPS of $6.16. The healthcare segment saw a 5% revenue growth in the fourth quarter, while the Applied Sterilization Technologies segment experienced a 9% increase. However, the Life Sciences segment faced a 7% revenue decline due to divestitures and reduced capital equipment sales. The company’s free cash flow also improved significantly to $787.2 million, primarily due to working capital enhancements.
Looking ahead, STERIS anticipates a 6-7% revenue growth for fiscal 2026, with adjusted earnings per share projected to rise between 7-10%. Despite potential challenges such as tariffs, the company remains optimistic about its ability to deliver value to shareholders through strategic investments and operational efficiencies.
Overall, STERIS’s financial performance in fiscal 2025 underscores its resilience and adaptability in a dynamic market, setting a solid foundation for continued growth and innovation in the coming year.